Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
DTIL
DTIL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest DTIL ETF News Today | Earnings, Events & Price Alerts
DTIL News
FDA Approval Enables Initiation of DMD Clinical Trial
Feb 11 2026
Newsfilter
Precision BioSciences Receives FDA Approval for Clinical Trial
Feb 11 2026
Yahoo Finance
Precision BioSciences Advances PBGENE-HBV and PBGENE-DMD Trials, Data Updates Expected in 2026
Jan 12 2026
Yahoo Finance
iECURE Secures FDA RMAT Designation for ECUR-506, Advancing OTC Deficiency Treatment
Jan 07 2026
Newsfilter
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
Dec 01 2025
NASDAQ.COM
Precision BioSciences Initiates $75 Million Stock and Warrant Sale
Nov 11 2025
SeekingAlpha
Precision BioSciences Unveils $75 Million Common Stock, Pre-Funded Warrants, and Warrant Offering
Nov 10 2025
Yahoo Finance
Precision BioSciences Unveils New Phase 1 PBGENE-HBV Findings at AASLD The Liver Meeting®, Highlighting Safety, Tolerability, and Dose-Dependent Antiviral Effects in Initial Three Cohorts
Nov 10 2025
Newsfilter
Precision BioSciences Publishes Study in Nucleic Acids Research on High-Efficiency Gene Insertion Mechanisms in Dividing and Non-Dividing Cells with ARCUS Nucleases
Oct 09 2025
Newsfilter
Precision BioSciences Unveils First U.S. Clinical Trial Site for ELIMINATE-B Study
Oct 07 2025
Newsfilter
DFAS's Assets May Indicate a 15% Profit Opportunity
Oct 02 2025
NASDAQ.COM
Precision BioSciences to Present Late-Breaking Poster at the 30th Annual World Muscle Society Congress
Sep 30 2025
Newsfilter
Precision BioSciences Shares Phase 1 ELIMINATE-B Trial Data for PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
Sep 12 2025
Newsfilter
Precision BioSciences Reveals U.S. Patent for PBGENE-HBV Targeting Chronic Hepatitis B and Provides Program Status Update
Sep 08 2025
Newsfilter
iECURE to Showcase Preliminary OTC-HOPE Clinical Trial Results for ECUR-506 in Ornithine Transcarbamylase Deficiency at the 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism
Aug 25 2025
Newsfilter
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Aug 06 2025
Newsfilter
Show More News
